The homeostatic blood protease, activated protein C (APC), exerts three distinct activities: (1) antithrombotic based on inactivation of clotting factors Va and VIIIa; (2) cytoprotective based on endothelial barrier stabilization and anti-inflammatory and anti-apoptotic actions, and (3) regenerative based on stimulation of neurogenesis, angiogenesis, and wound healing.
INTRODUCTION
The body employs a variety of mechanisms to maintain tissue homeostasis and minimize damage from excessive activation of the multiple host defense system components. The protein C system provides negative feedback regulation of host defense systems and also can promote balanced regeneration of key tissue components. This is evident from many basic lab studies, preclinical data and clinical observations. [1] [2] [3] [4] [5] [6] [7] [8] The groundwork for understanding the protein C system in man initially came from the discovery of severe protein C deficiency linked to neonatal purpura fulminans 9 which is fatal unless treated aggressively, 10 and of mild, heterozygous protein C deficiency linked to increased risk for venous thrombosis.
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Subsequently, targeted deletion of the murine protein C gene causes perinatal lethality with pathologic lesions in the brain. 12,13 Thus, both human and murine data prove protein C's essential physiologic roles as an antithrombotic and anti-inflammatory protein.
The protein C system's antithrombotic mechanisms and its utility for treating sepsis have been studied for decades. However, the remarkable ability of activated protein C (APC), a trypsin-like serine protease, to initiate beneficial cell signaling is a recent topic for investigation. 1, 5, [14] [15] [16] APC initiates cell signaling that drives multiple, diverse, independent types of cellular activities, many of which are termed cytoprotective activities, comprising antiapoptotic and anti-inflammatory activities, favorable alterations of gene expression, and stabilization of endothelial barriers. Furthermore, APC-initiated signaling can favorably drive cell proliferation and differentiation as well as angiogenesis, thus, defining actions of APC that make it attractive for pharmacologic therapies where cell and tissue regeneration is important, such as for neurogenesis in the setting of ischemic stroke 17, 18 and for wound healing.
14 For personal use only. on June 9, 2017. by guest www.bloodjournal.org From involve altered gene expression profiles. 21, 22 , see 1 Additional receptors besides those shown ( Fig.   1 ) may be required for APC's regenerative properties, e.g., PAR3 and S1P1 for neurogenesis 18 and PAR2, EGFR, and Tie-2 for wound healing. 14, 20 Inactivation of circulating APC by plasma serine protease inhibitors (SERPINS, upper left) is a major mechanism for clearance of APC.
Plasma protein C zymogen normally circulates at 70 nM in man, and human plasma contains ~ 40 pM circulating APC. 1 In healthy subjects, protein C has a half-life of 8 hr while pharmacologic APC has a half-life of 15-20 min, 23 and murine APC has a half-life of 12-14 min.
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APC: Mechanisms for PAR1-mediated biased signaling
A particularly difficult conundrum arose when extensive studies showed that PAR1 mediates thrombin's disruption of endothelial barrier leading to vascular leakage while, paradoxically, PAR1 mediates APC's endothelial barrier protection, preventing vascular leakage. 25, 26 Similarly, PAR1 mediates some of thrombin's proinflammatory actions whereas PAR1 mediates APC's anti-apoptotic and anti-inflammatory activities. The solution to this conundrum is based on the ability of G protein coupled receptors (GPCR) to initiate entirely different signaling pathways when stimulated by different "biased" agonists. [27] [28] [29] PAR1, like some other GPCRs, is capable of biased signaling which occurs either via G proteins or via β -arrestin-2. 30, 31 Multiple considerations help to define and understand PAR1 biased signaling. First, different subpopulations of PAR1 are localized in membranes that lack caveolin-1 ( Fig. 2A ) or in caveolae microdomains that also contain EPCR (Fig. 2B) . 32, 33 Second, PAR1 signaling is initiated by different tethered N-terminal peptide sequences arising from different cleavages in the extracellular N-terminus either the canonical Arg41 thrombin cleavage
For personal use only. on June 9, 2017. by guest www.bloodjournal.org From site (i.e., widely recognized as the essential thrombin cleavage site) or the novel APC Arg46 cleavage site (Fig. 2C) . 31, 34, 35 Third, following thrombin cleavage, PAR1 initiates signaling involving G proteins, ERK1/2 and RhoA, or alternatively, following APC cleavage at Arg46, PAR1 initiates signaling involving β -arrestin-2, PI3K/Akt, and Rac1 (Fig. 2D) . Fourth, peptides mimicking the N-terminus of cleaved PAR1 are peptide agonists with pharmacologic effects resembling those of the respective proteases that cleave PAR1 differentially. For example, 6-mer or 10-mer "thrombin receptor activating peptides (TRAP)" that begin with Ser-42 promote G protein-mediated signaling similar to thrombin whereas a 20-mer peptide that begins with Asn-47 (TR47) promotes APC-like signaling (Fig. 2D ). Endothelial cell studies show that TRAP but not TR47 promotes ERK1/2 phosphorylation whereas TR47 but not TRAP promotes Akt phosphorylation ( Fig. 2E) . 31 Thrombin and TRAP peptides cause endothelial barrier disruption and pro-inflammatory effects whereas APC and the TR47 peptide cause barrier protective and anti-inflammatory effects (Fig. 2E) . Hence, the same GPCR, PAR1, is capable of biased signaling with absolutely opposing outcomes for the cell, the tissue, and the host depending on which coagulation system protease, thrombin or APC, is cleaving PAR1.
PAR1 is subject to cleavages at residues other than Arg41 or Arg46. For example, MMP-1 cleaves at Asp39 and seems to result in signaling that somewhat resembles that of thrombin. 36 Elastase cleaves PAR1 at Leu45, and in vitro signaling effects differ somewhat from those of thrombin. 27, 37 The in vivo importance and consequences of these alternative cleavages in PAR1 by other proteases are not yet as clear as are those for the actions of thrombin and APC.
For personal use only. on June 9, 2017. by guest www.bloodjournal.org From
EPCR, PAR1, PAR2 and PAR3 functional interrelationships
Non-canonical PAR1 cleavage and activation by APC (Fig. 2C ) combined with PAR1 biased signaling via β -arrestin 2 (Fig. 2D ) enabled understanding the selectivity and the diversity of signaling repertoires initiated by thrombin and APC. PAR3 also contributes to APC's protective effects in the brain 18, 38 and kidney, 39 and PAR3 also manifests functional selectivity caused by APC versus thrombin. Non-canonical PAR3 cleavage by APC at Arg41, in contrast to the canonical cleavage of PAR3 by thrombin at Lys38 (Fig. 3) , generates distinct N-terminal tethered-ligand sequences that modulates different signaling cascades. 40, 41 For example, a peptide beginning with the PAR3 residue 39 promotes PAR1-mediated ERK1/2 phosphorylation that results in endothelial barrier disruptive effects. In contrast, a peptide begining with PAR3
residue 42 can promote APC-like barrier protective and vascular protective benefits in vitro and in vivo. Although functional outcomes of non-canonical PAR1 and PAR3 peptides may sometimes overlap (e.g., endothelial barrier protection), 31,40 the mechanisms of action and signaling pathways involved are clearly distinct. The APC-derived TR47 PAR1 peptide induces Akt activation (Fig. 2E ) but the APC-derived PAR3 tethered-ligand peptide that begins with residue 42 induces activation of Tie2 resulting in upregulation of ZO-1 and stabilization of tight junctions. 31, 41 Thus, the functional effects of non-canonical tethered-ligand peptides are remarkable, 41 and show that the diverse cellular effects of APC can arise from activation of multiple receptor complexes.
The PAR interactome: novel concepts for signaling selectivity and specificity
PAR3 is considered a non-signaling receptor yet shows remarkable signaling selectivity. Thus, other PAR3-effector interactions are required for signal induction, diversification, and regulation
For personal use only. on June 9, 2017. by guest www.bloodjournal.org From (Fig. 3) Here we refer to the PAR interactome (Fig. 3) as a collection of components whose interactions are key for the functional selectivity of APC's beneficial cytoprotective and regenerative protease signaling. Potential GPCR interactomes are exceedingly complex, e.g. proteomics identified >200 proteins pulled-down with the β 2-adrenergic receptor. 50 The complexity of this PAR interactome increased considerably in recent years due to (1) the non-canonical activation of multiple PARs by multiple proteases; (2) the realization that both PAR1 and PAR2 are capable of biased signaling; and (3) the potential for the formation of PAR-PAR homodimers and heterodimers. Given these complexities (Fig. 3) , understanding of the molecular mechanisms involved in the functional selectivities of the PAR interactome signaling molecules provide unique challenges and opportunities for novel discoveries with potential immediate relevance to targeted therapeutic strategies in a variety of diseases (Tables 1 & 2) .
Directing of the PAR interactome by EPCR
EPCR plays an integral role in the PAR interactome. EPCR functions as a co-receptor facilitating APC-mediated activation of PARs, 51-53 but also can potentially serve as an allosteric modulator 54 of PAR1 signaling. This latter point became evident from the switch in thrombin's functional selectivity from endothelial barrier disruptive to barrier protective upon "EPCR Regardless of the explanation(s), the regulation of the PAR interactome in time and space may provide a basis for regulation of functional selectivity of protease signaling and may provide mechanistic explanations for how PARs affect the stage-specificity of disease progression and of success or failure for therapeutic interventions that target PARs.
APC: Translation to Preclinical Therapies
Stimulated by discovery of hereditary mild and severe protein C deficiencies, 9,11 preclinical studies initially used baboons to show that human plasma-derived wt-APC was antithrombotic and that it reduced death caused by E. coli. [64] [65] [66] Subsequently, many laboratories provided evidence of the beneficial properties of wt-APC and APC variants across a broad spectrum of preclinical animal injury models, as briefly highlighted below.
Wildtype APC: Preclinical Studies
Multiple preclinical studies employed human or recombinant murine wildtype (wt) APC and injury models (Table 1) . Based on the diversity of benefits, the breadth of APC's effects in preclinical injury models is astounding. Pharmacologic APC promotes in vivo homeostasis and healing in the brain, heart, lungs, kidney, gastrointestinal tract, spleen, eye, bone marrow, and skin. These data for preclinical research ( Space does not permit the discussion of all of the promising in vivo studies listed in Table 1 . Thus, the reader is referred to other reviews for more extensive commentaries concerning the in vivo and relevant in vitro studies of APC's benefits (Table 1) . 1, 5, 6, 14, 16, 60, 72 
APC variants: Preclinical Studies
Clinical studies showed that recombinant wt-APC therapy increases risk for serious bleeding, [73] [74] [75] implying that APC mutants which have reduced anticoagulant activity but retain normal cellsignaling actions should enable APC therapies with reduced risk of bleeding complications.
Preclinical studies of the signaling-selective APC mutants, 5A-APC, 3K3A-APC, APC-2Cys, K193E-APC, and of an anticoagulant-selective APC mutant, E149A-APC, have proven invaluable to clarify which one of APC's two broad types of actions, namely anticoagulant or cytoprotective, is more important or essential for reducing injury in preclinical injury models ( Table 2) .
76-81
In studies of death caused by endotoxin or bacteremia, the signaling-selective recombinant 5A-APC mutant reduced mortality whereas the anticoagulant-selective E149A-APC mutant failed to reduce death. 78, 80 Mortality reduction by 5A-APC required EPCR and PAR1.
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Similarly, 5A-APC stabilized the pulmonary vasculature and reduced death caused by P.
aeruginosa, confirming a primary role for APC's cell signaling activities. 82 Thus, the cellsignaling actions of APC involving PAR1 and EPCR are key for reducing death in murine sepsis models. Importantly, this mechanism of action contrasts with one of the central concepts that drove the development last century of recombinant wt-APC for sepsis therapy which emphasized that APC would reduce organ failure by preventing or reducing consumptive coagulopathy and disseminated intravascular coagulation. Indeed, the dosing of wt-APC for multiple clinical trials for sepsis 75 involved low-dose APC infusion for 96 hr which seems rather suboptimal for therapeutic agents that act by resetting cell signaling networks.
When the signaling-selective recombinant 5A-APC or 3K3A-APC mutants were used to treat various brain injuries, they were at least as effective as wt-APC for reducing brain injuries caused by ischemic stroke, traumatic brain injury or amyotrophic lateral sclerosis (ALS) ( Tables   1 and 2 ). Signaling-selective variants were effective for promoting neurogenesis, emphasizing the primary role for APC's cell signaling activities for neuroprotection (see below).
A signaling-selective APC variant designated "APC-2Cys" 76 was as good as or better than wt-APC for cardioprotection against I/R injury.
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Preclinical studies of neuroprotective activity of wt-APC and APC variants
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Brain preclinical injury studies have provided extensive information and insights about APC. [1] [2] [3] 6, 38, [83] [84] [85] The neuroprotective activities of APC are seen in its ability to reduce brain damage caused by I/R injury and to reduce tPA-induced bleeding following I/R injury (Fig. 4) .
In spite of preclinical and clinical testing of hundreds of agents for ischemic stroke therapies, only tissue plasminogen activator (tPA) has been clinically approved. Because tPA can promote hemorrhagic transformation of an ischemic stroke, it must be used within < 4.5 hr of onset of stroke, limiting its efficacy. Moreover, tPA is neuronal toxic. The neuroprotective effects of APC remarkably include reduction of tPA'a neurotoxic side effects. For example, in murine ischemic stroke models, APC reduced tPA-induced bleeding in the brain (Figs. 4D, 4E) .
Notably, the ability of APC to reduce tPA-induced bleeding required PAR1 which was a major indication for this receptor's in vivo role. APC also reduced tPA-induced increases in MMP9 that contribute to stroke damage.
Studies indicate that APC directly benefits not only brain microvascular endothelial cells but also neurons. The direct in vivo neuronal protective effects of APC were shown in murine NMDA excitotoxic injury models and in vitro using cultured neurons. 38, 86 Like wt-APC, the signaling-selective 5A-APC and 3K3A-APC mutants with reduced anticoagulant activity showed neuroprotective activities that were at least as potent as those of wt-APC, and their neuroprotective abilities required PAR1 (Tables 1, 2 ). For initial research using signaling-selective APC variants, we focused on murine 5A-APC that carries 5 Ala mutations because it has < 10 % residual anticoagulant activity. However, for translation to clinic, we focused on recombinant human 3K3A-APC which also has < 10 % anticoagulant activity due to three Lys to Ala mutations in a surface-exposed loop containing (Fig.   5A , 5B).
Recombinant human 3K3A-APC was neuroprotective and extended the therapeutic window for tPA. 89 It was neuroprotective when therapy was initiated beginning 4 hr after onset of ischemia and when a repeated bolus dosing regimen was employed. 74, 75 ).
What are the lessons to be learned from clinical data from sepsis trials, including data for wt-APC? In the 1990's, a prevailing concept was that organ dysfunction and failure leading to death in sepsis were driven by intravascular coagulation which was intimately intertwined with inflammation. Thus, APC and two other anticoagulants, antithrombin and tissue factor pathway inhibitor, were studied in phase III trials, 73, 94, 95 and only the PROWESS trial was positive.
Reflecting mechanistic emphasis on anticoagulation, wt-APC therapy employed a 96 hr infusion of low dose wt-APC. But the mechanism of action for APC for sepsis in preclinical models was then not understood. Proof for the major role for APC's cell signaling actions causing cytoprotective and immunoregulatory actions rather than its anticoagulant actions came after
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. 22, 43, 77, 78, 80 Hence, a 96-hour, low-dose wt-APC infusion was not optimally suited to harness APC's cell signaling actions. We believe that bolus dosing is preferred to promote potent endothelial barrier stabilization via PAR1 signaling and Rac1 activation and to alter gene expression profiles that promote anti-apoptotic and anti-inflammatory activities. Future clinical studies in sepsis should be considered for signaling-selective APC variants using optimal
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3K3A-APC variant: Trial for ischemic stroke therapy
Recent clinical studies are centered on the signaling-selective variant, 3K3A-APC, for ischemic stroke based on extensive preclinical mechanism of action data which emphasize cell signaling as essential and based on greatly reduced risk of bleeding by this variant that has < 10 % of APC's anticoagulant activity.
89-91,96 3K3A-APC was neuroprotective and extended the therapeutic window for tPA. 89 It was neuroprotective when therapy was initiated beginning 4 hr after onset of ischemia and when a repeated bolus dosing regimen was employed. 89,90 3K3A-APC was neuroprotective in the presence of comorbidities exemplified in hypertensive rats or in aging female mice. 91 Notably, in vivo and in vitro studies showed that 3K3A-APC promoted neurogenesis in the post-ischemic mouse brain and in human embryo-derived neuroprogenitor cell cultures, respectively.
17,18,90
The phase I safety study in normal subjects showed that high dose bolus regimens using 3K3A-APC are safe (Fig. 5C ). 23 Remarkably, the very high transient levels of 3K3A-APC which were well tolerated (e.g., plasma levels of 4,500 ng/ml) differ markedly from sepsis therapy that provided wt-APC plasma levels of ≤ 50 ng/ml for 4 days. Currently, a phase II dose-escalation safety study of 3K3A-APC for ischemic stroke is underway using the NIH-funded "NeuroNext"
clinical trial network (see http://www.neuronext.org/neuronext-pleased-announce-funding-ourfourth-approved-trial-safety-evaluation-3k3a-apc-ischemic).
Wild type-APC: Studies of wound healing and ischemic retinal injury
Following an initial open label study of wt-APC for wound healing of diabetic ulcers, Jackson and colleagues undertook a limited, double blind study that showed significant benefits for wt-APC for diabetic ulcers which justifies further clinical trials. 14, 97, 98 Based on the preclinical data showing APC benefits for I/R injury to the brain, 99 Kamei and colleagues initiated ongoing openlabel studies of wt-APC administered directly by injection into the eye for ischemic retinal injury which appears promising 100 and which should lead to double-blind studies to clarify the real benefits of APC therapy for the ischemic damage to the retina.
Future Directions
The remarkably broad range of injuries (Tables 1, 2) for which APC or its variants provide pharmacologic benefits in preclinical studies makes it compelling to seek translation to the clinic. 1 9 R e f e r e n c e L i s t For personal use only. on June 9, 2017. by guest www.bloodjournal.org From 0
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For personal use only. on June 9, 2017. by guest www.bloodjournal.org From For personal use only. on June 9, 2017. by guest www.bloodjournal.org From causes APC-like effects on cells . 31, 34, 118 This is illustrated by the differences in phosphorylations of ERK1/2 compared to Akt (E) as TRAP induces phosphorylation of ERK1/2 but not Akt whereas TR47 induces phosphorylation of Akt but not ERK1/2). When APC was given 10 min after onset of murine MCAO, it had beneficial effects on motor neurological score (A), total brain infarct volume (B) and post-ischemic cerebral blood flow (C). In MCAO studies, tPA was given and tPA-induced brain hemorrhage was visualized
as Hb leakage at 24 h (tPA, 0.2 mg/kg) (D). For other studies, mice received either 0.2 mg/kg APC with tPA or 2.0 mg/kg APC at 3h post-tPA, and bleeding in the ischemic hemisphere was quantified (E), showing that APC decreased tPA-induced bleeding. Similar studies using PAR1
For personal use only. on June 9, 2017. by guest www.bloodjournal.org From null mice (PAR1 -/-) showed that PAR1 was required for the ability of APC to prevent tPA-induced bleeding (F). Panels A-C are from Cheng et al. 84 and panels D-F are from Cheng et al.
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Figure 5. 3K3A-APC with reduced anticoagulant activity but normal cytoprotective activity is safe in man when given as high-dose bolus regimen.
The polypeptide ribbon model of APC depicts the N-terminal Gla domain at the bottom which binds EPCR and phospholipid membranes, the EGF-1 and EGF-2 domains in the middle, and the protease domain at the top with the ''active site'' triad residues (His211, Asp257, Ser360) labeled in red (A). Blue coloring highlights three Lys residues (KKK191-193) on top of the protease domain which form a positively charged exosite that recognizes factor Va.
Mutation of these Lys residues to Ala residues in the human APC variant, 3K3A-APC, deletes a factor Va binding site and consequently reduces anticoagulant activity by > 90 % (B, left side) but does not affect 3K3A-APC's anti-apoptotic activity when tested in endothelial cell apoptosis assays (panel B, right side). This 3K3A-APC variant is designated to be "signaling-selective"
since it lacks most anticoagulant activity but retains normal cell signaling actions. In a phase 1 clinical study of 3K3A-APC, high dose boluses were safe when administered to healthy adults (C) (taken from 23 ) and formed the basis for an FDA approval of phase 2 study of 3K3A-APC in ischemic stroke patients (see http://www.neuronext.org/neuronext-pleased-announce-fundingour-fourth-approved-trial-safety-evaluation-3k3a-apc-ischemic). 
